In the Realm of Chemistry, asymmetric synthesis has prime importance as it allows the creation of optically pure chemical entities. The synthesis of a preferred enantiomer is highly desirable when seeking specific biological activities owing to the importance of chirality. A highly enantioselective synthesis can be achieved using asymmetric catalysis. Most asymmetric reactions use homogeneous versions of organocatalysts, which are expensive; at the end of a reaction, such catalysts can’t be recycled and often require more extended and wasteful reaction work-up’s. In contrast, immobilization processes lead to heterogenized asymmetric organocatalysts where the active species is anchored on a solid-support to offer optimal characteristics (inexpensive, robust, reusable and highly stable). AsymmFlow delineates synthesis, characterization, and application of novel asymmetric supported organocatalysts for enantioselective cyclization in continuous flow/batch to produce tetrahydro-β-carboline (THβC) derivatives. The main aim of the AsymmFlow project is to combine continuous flow processes and organocatalysis for developing a sustainable protocol for enantioselective cyclization reactions. We believe that the use of asymmetric supported organocatalysts will solve the problem of common synthetic challenges such as poor enantioselectivity, scale-up issue, and prolonged reaction times in the synthesis of tetrahydro-β-carboline (THβC) derivatives, including pharmacologically relevant objectives such as Tadalafil. The multidisciplinary nature of AsymmFlow will open a window by enhancing the scientific as well as the technical potential of Dr. Moreshwar to gain the transition from researcher to the principal investigator and accomplish his career goals.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement 890452